Achillion Pharmaceuticals (ACHN) Announces Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Achillion Pharmaceuticals (NASDAQ:ACHN) posted its earnings results on Wednesday. The biopharmaceutical company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.02, MarketWatch Earnings reports.

ACHN traded down $0.07 during trading on Thursday, hitting $2.99. The company’s stock had a trading volume of 812,700 shares, compared to its average volume of 1,479,922. Achillion Pharmaceuticals has a twelve month low of $2.33 and a twelve month high of $4.34. The firm has a market cap of $408.83 million, a P/E ratio of -4.82 and a beta of 1.69.

Separately, BidaskClub raised Achillion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, September 1st. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $4.38.

ILLEGAL ACTIVITY NOTICE: This article was reported by WKRB News and is the sole property of of WKRB News. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.

See Also: Discover Your Risk Tolerance

Earnings History for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply